**10. Conclusion**

Ischemic heart disease is the heart disease in which most often there is indication for an ICD implantation. However, after placed, these devices are used in a minority of patients in the context of primary prevention.

Left ventricular dysfunction remains the most robust parameter in the decision to implant an ICD. All therapeutic measures that can accelerate or improve myocardial reperfusion by contributing to the preservation of ventricular function are undoubtedly the best strategies to reduce costs associated with ICDs.

cardiography and Arrhythmias and Council on Epidemiology and Prevention. Circu‐

Sudden Death in Ischemic Heart Disease http://dx.doi.org/10.5772/52661 53

[6] Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myo‐ cardial infarction and the postinfarction period. Am J Cardiol. 1997; 80(9B): 35J-9J.

[7] Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sota‐

[8] Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, et al. Costeffectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: re‐ sults from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation.

[9] Weaver WD, Cobb LA, Hallstrom AP, Fahrenbruch C, Copass MK, Ray R. Factors in‐ fluencing survival after out-of-hospital cardiac arrest. J Am Coll Cardiol. 1986; 7(4):

[10] A comparison of antiarrhythmic-drug therapy with implantable defibrillators in pa‐ tients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics ver‐ sus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997; 337(22):

[11] Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian im‐ plantable defibrillator study (CIDS) : a randomized trial of the implantable cardi‐

[12] Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhyth‐ mic drug therapy with implantable defibrillators in patients resuscitated from car‐ diac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102(7):

[13] Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Metaanalysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur

[14] Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular ar‐ rhythmias and the prevention of sudden cardiac death: a report of the American Col‐ lege of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Pre‐

vention of Sudden Cardiac Death). J Am Coll Cardiol. 2006; 48(5): e247-346.

overter defibrillator against amiodarone. Circulation. 2000; 101(11): 1297-302.

lation. 2008; 118(14): 1497-518.

lol. Lancet. 1996; 348(9019): 7-12.

2006; 114(2): 135-42.

752-7.

1576-83.

748-54.

Heart J. 2000; 21(24): 2071-8.

In recent years numerous studies have been performed using non-invasive methods for di‐ agnosis of autonomic dysfunction or anatomic-functional abnormalities but it remains a need for a proper validation of predictors of arrhythmic death.
